|Source:||The herbs of Berchemia kulingensis Schneid|
|Biological Activity or Inhibitors:||1. (-)-Epigallocatechin(EGC) has prominent antiplatelet activity and blood anticoagulation in a dose-dependent manner.
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||3.2648 mL||16.3239 mL||32.6477 mL||65.2955 mL||81.6193 mL|
|5 mM||0.653 mL||3.2648 mL||6.5295 mL||13.0591 mL||16.3239 mL|
|10 mM||0.3265 mL||1.6324 mL||3.2648 mL||6.5295 mL||8.1619 mL|
|50 mM||0.0653 mL||0.3265 mL||0.653 mL||1.3059 mL||1.6324 mL|
|100 mM||0.0326 mL||0.1632 mL||0.3265 mL||0.653 mL||0.8162 mL|
Food Funct. 2013 Oct;4(10):1521-5.
|Blood anticoagulation and antiplatelet activity of green tea (-)-epigallocatechin (EGC) in mice.[Pubmed: 24056410]|
|(-)-Epigallocatechin(EGC) was prepared from green tea polyphenols through column chromatography of a polyamide (3.6 × 40 cm). Three dosages of EGC (0.25, 0.5, 1.0 g kg(-1) d(-1)) were ingested respectively by ICR mice via gavage. Compared with the control group, group (-)-Epigallocatechin(EGC) 0.5 (dosage, 0. 5 g kg(-1) d(-1)) and group (-)-Epigallocatechin(EGC) 1.0 (dosage, 1.0 g kg(-1) d(-1)) presented significant inhibition on platelet aggregation in mice accompanied by 18.4 and 25.6% of inhibition ratio, respectively. The bleeding times (BT) of mice in group (-)-Epigallocatechin(EGC) 0.5 and group EGC1.0 were significantly prolonged (P < 0.01) as well as blood clotting time (BCT) in group (-)-Epigallocatechin(EGC) 1.0 (P < 0.05). All three dosages of EGC prolonged activated partial thromboplastin time (APTT) significantly (P < 0.01), but had no prominent effect on prothrombin time (PT) and fibrinogen level which indicated that the anticoagulation of (-)-Epigallocatechin(EGC) could not be attributed to the level decrease of coagulation factor such as fibrinogen. The results demonstrated that EGC had prominent antiplatelet activity and blood anticoagulation in a dose-dependent manner.|
Arch Microbiol. 2014 Oct;196(10):681-95.
|Isolation and characterization of rat intestinal bacteria involved in biotransformation of (-)-epigallocatechin.[Pubmed: 24947740]|
|Two intestinal bacterial strains MT4s-5 and MT42 involved in the degradation of (-)-Epigallocatechin(EGC) were isolated from rat feces. Strain MT4s-5 was tentatively identified as Adlercreutzia equolifaciens. This strain converted (-)-Epigallocatechin(EGC) into not only 1-(3, 4, 5-trihydroxyphenyl)-3-(2, 4, 6-trihydroxyphenyl)propan-2-ol (1), but also 1-(3, 5-dihydroxyphenyl)-3-(2, 4, 6-trihydroxyphenyl)propan-2-ol (2), and 4'-dehydroxylated (-)-Epigallocatechin(EGC) (7). Type strain (JCM 9979) of Eggerthella lenta was also found to convert (-)-Epigallocatechin(EGC) into 1. Strain MT42 was identified as Flavonifractor plautii and converted 1 into 4-hydroxy-5-(3, 4, 5-trihydroxyphenyl)valeric acid (3) and 5-(3, 4, 5-trihydroxyphenyl)-γ-valerolactone (4) simultaneously. Strain MT42 also converted 2 into 4-hydroxy-5-(3, 5-dihydroxyphenyl)valeric acid (5), and 5-(3, 5-dihydroxyphenyl)-γ-valerolactone (6). Furthermore, F. plautii strains ATCC 29863 and ATCC 49531 were found to catalyze the same reactions as strain MT42. Interestingly, formation of 2 from (-)-Epigallocatechin(EGC) by strain MT4s-5 occurred rapidly in the presence of hydrogen supplied by syntrophic bacteria. Strain JCM 9979 also formed 2 in the presence of the hydrogen or formate. Strain MT4s-5 converted 1, 3, and 4 to 2, 5, and 6, respectively, and the conversion was stimulated by hydrogen, whereas strain JCM 9979 could catalyze the conversion only in the presence of hydrogen or formate. On the basis of the above results together with previous reports, the principal metabolic pathway of (-)-Epigallocatechin(EGC) and EGCg by catechin-degrading bacteria in gut tract is proposed.|